Procurement Summary
Country : Germany
Summary : Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Substance Ixekizumab
Deadline : 08 Nov 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 74574551
Document Ref. No. : 632061-2022
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
§130a paragraph 8 SGB V enables the health insurance companies (KK) and pharmaceutical companies to conclude framework discount agreements on the drugs to be dispensed at the expense of the statutory KK. The GWQ is registered as a company for economy and quality at KK according to § 130a Abs. 8 S. 5 SGB V for their Aknational and customer checkouts. With regard to the relevant legal regulations for the award of public contracts, a regular process of active substance-related, formal award procedures takes place by GWQ ServicePlus AG in accordance with the regulations of Part 4 of the GWB. Until IWhen new drug discount agreements come into force, the GWQ would like to conclude drug discount agreements with all interested pharmaceutical companies as part of the open house procedure for preparations with the u. a. complete active substance. The earliest contract start date is 1/1/2023.
Doc Title: Pharmaceuticalproducts
Contract Type: Supplies
Document Type : Contract notice
Reference Number : 2022/S 220-632061
Contract Type : Supplies
33600000 - Pharmaceutical products
Authority Type : Body governed by public law
Type of Procedure : Open procedure
Regulation : European Union
Bid Type : Submission for all lots
Doc Title : Pharmaceutical products
Dispatch Date : 2022-11-10
Publish Date : 2022-11-15
Submission Date : 2024-11-08
Documents
Tender Notice